NexGel (NXGL) Stock Price, News & Analysis

Company Overview

NexGel, Inc. is a clinical-stage biotechnology company focused on developing sustained-release drug delivery platforms for ophthalmic and other indications. The company’s core technology leverages proprietary hydrogel and polymer chemistries to create injectable or implantable depots that release therapeutic agents over extended periods. By reducing the frequency of administrations, NexGel aims to improve patient compliance, minimize peak-to-trough fluctuations in drug levels and enhance overall treatment outcomes.

The company’s lead programs target eye diseases with high unmet needs. NGX-401 is an injectable dexamethasone hydrogel under investigation for indications such as diabetic macular edema and uveitic macular edema, while NGX-101 is designed for sustained release of antiglaucoma medications. In preclinical studies and early-phase clinical trials, these formulations have shown controlled drug-release profiles, favorable safety characteristics and the potential to supplant more frequent dosing regimens. Beyond ophthalmology, NexGel is exploring strategic partnerships to adapt its delivery platform for dermatology and other therapeutic areas.

Headquartered in the United States, NexGel was founded to translate innovative polymer science into practical drug delivery solutions. The company is led by a management team with deep expertise in pharmaceutical research, development and commercialization, supported by a scientific advisory board comprised of leaders in ophthalmology and drug-delivery technologies. NexGel currently focuses on the U.S. market, with plans to expand globally through licensing, co-development and manufacturing collaborations. By harnessing its hydrogel platform, NexGel aims to redefine treatment paradigms for chronic diseases that benefit from sustained drug exposure.

Key Stats

• Today's Range: $2.31 to $2.53
• 50-Day Range: $2.12 to $2.76
• 52-Week Range: $2.00 to $5.10
• Volume: 93,114 shs
• Average Volume: 71,393 shs
• Market Capitalization: $18.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NexGel Stock Analysis - MarketRank™

NexGel scored higher than 14% of companies evaluated by MarketBeat, and ranked 878th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NexGel.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NexGel is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NexGel is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NexGel has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of NexGel has been sold short.

Short Interest Ratio / Days to Cover

NexGel has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NexGel has recently increased by 20.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NexGel does not currently pay a dividend.

Dividend Growth

NexGel does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.02% of the float of NexGel has been sold short.

Short Interest Ratio / Days to Cover

NexGel has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NexGel has recently increased by 20.27%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

NexGel has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NexGel this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NexGel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,310.00 in company stock.

Percentage Held by Insiders

20.55% of the stock of NexGel is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.21% of the stock of NexGel is held by institutions.

NXGL Stock Analysis - Frequently Asked Questions

How have NXGL shares performed this year?

NexGel's stock was trading at $4.46 at the start of the year. Since then, NXGL shares have decreased by 46.0% and is now trading at $2.41.

How were NexGel's earnings last quarter?

NexGel, Inc. (NASDAQ:NXGL) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The business had revenue of $2.81 million for the quarter, compared to the consensus estimate of $2.73 million. NexGel had a negative net margin of 30.80% and a negative trailing twelve-month return on equity of 54.95%.
Read the conference call transcript.

When did NexGel IPO?

NexGel (NXGL) raised $14 million in an initial public offering (IPO) on Wednesday, December 22nd 2021. The company issued 2,100,000 shares at a price of $6.83 per share. Maxim Group LLC served as the underwriter for the IPO.

How do I buy shares of NexGel?

Shares of NXGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NexGel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NexGel investors own include Lexicon Pharmaceuticals (LXRX), Aditxt (ADTX), Helius Medical Technologies (HSDT), Onconova Therapeutics (ONTX), EchoStar (SATS), American Battery Technology (ABML) and Aumann (AAG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NXGL
• CIK: 1468929
• Web: nexgel.com
• Phone: 215-702-8550
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.28 million
• Net Margins: -30.80%
• Pretax Margin: -31.64%
• Return on Equity: -54.95%
• Return on Assets: -27.84%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.88
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $8.69 million
• Price / Sales: 2.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 7,650,000
• Free Float: 6,082,000
• Market Cap: $18.44 million
• Optionable: Not Optionable
• Beta: 0.59